Stock events for LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics' stock price has decreased by approximately 70.59% in the past six months. In December 2025, the stock declined following an FDA adverse event report of a retinal tear in a patient using VIZZ eye drops, leading to a 42% drop over 10 days. The company emphasized the patient's pre-existing conditions, and analysts suggested the market reaction was an overreaction. The stock's 52-week high was $50.40, and its low was $11.48. After LENZ reported earnings on January 7, 2026, its shares declined by 6.6%.
Demand Seasonality affecting LENZ Therapeutics, Inc.’s stock price
Specific demand seasonality for LENZ Therapeutics, Inc.'s products is not explicitly available. Demand might be relatively consistent throughout the year, given that VIZZ addresses presbyopia, an age-related vision condition. Potential seasonality may not yet be clearly established or reported due to the company's early stages of commercialization.
Overview of LENZ Therapeutics, Inc.’s business
LENZ Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for vision improvement, particularly for presbyopia, which affects a large global population. Their major product is VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved aceclidine-based eye drop for presbyopia, designed to restore near vision for up to 10 hours. The company was founded in 2013 and changed its name from Presbyopia Therapies, Inc. in June 2021.
LENZ’s Geographic footprint
LENZ Therapeutics, Inc. is headquartered in Solana Beach, California, and is actively commercializing VIZZ in the United States. The company has also established licensing partnerships to expand international access to VIZZ in regions including the Middle East, South Korea, Southeast Asia, Canada, and China.
LENZ Corporate Image Assessment
LENZ Therapeutics' brand reputation has been shaped by the launch of VIZZ eye drops in October 2025 and the "Make it VIZZable" consumer campaign featuring Sarah Jessica Parker in January 2026. However, an FDA adverse event report in December 2025, linking a retinal tear to VIZZ, led to a stock price drop and investor apprehension, creating a "perceived safety overhang."
Ownership
LENZ Therapeutics, Inc. has a diverse ownership structure, including institutional investors, insiders, and public/individual investors. As of March 3, 2026, there were 204 institutional owners and shareholders holding a total of 35,342,619 shares. Major institutional owners include RA Capital Management, L.P., FMR LLC, Falcon Edge Capital, LP, Versant Venture Management, LLC, and BlackRock, Inc.
